Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and <i>Helicobacter pylori</i> antibody titerTakeichi Yoshida, Masao Ichinose, Jun Kato et al.|International Journal of Cancer|2013Cited by 178
Eradication of <i>Helicobacter pylori</i> prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levelsKimihiko Yanaoka, Masao Ichinose, Masashi Oka et al.|International Journal of Cancer|2009Cited by 136
Cancer High-Risk Subjects Identified by Serum Pepsinogen Tests: Outcomes after 10-Year Follow-up in Asymptomatic Middle-Aged MalesKimihiko Yanaoka, Masao Ichinose, Masashi Oka et al.|Cancer Epidemiology Biomarkers & Prevention|2008Cited by 116
Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and <i>Helicobacter pylori</i> antibody together with endoscopic rugal hyperplastic gastritisMika Watanabe, Masao Ichinose, Izumi Inoue et al.|International Journal of Cancer|2012Cited by 107
Risk of gastric cancer in asymptomatic, middle‐aged Japanese subjects based on serum pepsinogen and <i>Helicobacter pylori</i> antibody levelsKimihiko Yanaoka, Masao Ichinose, Masashi Oka et al.|International Journal of Cancer|2008Cited by 77